INTERFERON A--PROLONGATION OR PERMANENCE OF THE HONEYMOON PERIOD IN DIABETES

$15,114M01FY2000RRNIH

University Of Texas Hlth Sci Ctr Houston, Houston TX

Investigators

Linked publications & trials

Paper 38470450 Paper 37671726 Paper 30341055 Paper 27245413 Paper 25896533 Paper 25581630 Paper 25311695 Paper 24838411 Paper 23983008 Paper 23928737 Paper 23464806 Paper 23097327 Paper 23042639 Paper 23020860 Paper 23007245 Paper 22990216 Paper 22853856 Paper 22343096 Paper 22200681 Paper 22190480 Paper 21978691 Paper 21813841 Paper 21712727 Paper 21684451 Paper 21607132 Paper 21353923 Paper 21048846 Paper 20977343 Paper 20971774 Paper 20734336 Paper 20696771 Paper 20637752 Paper 20627945 Paper 20576209 Paper 20569762 Paper 20498010 Paper 20391489 Paper 20391486 Paper 20212402 Paper 20118158 Paper 20017695 Paper 20001789 Paper 19918038 Paper 19850658 Paper 19796918 Paper 19775197 Paper 19762396 Paper 19717548 Paper 19717036 Paper 19714612 Paper 19667844 Paper 19644777 Paper 19578107 Paper 19565552 Paper 19553282 Paper 19540518 Paper 19531645 Paper 19479701 Paper 19454606 Paper 19406870 Paper 19301973 Paper 19233884 Paper 19231805 Paper 19204522 Paper 19132123 Paper 19099374 Paper 19081024 Paper 19017985 Paper 19004040 Paper 18954843 Paper 18954631 Paper 18761598 Paper 18759263 Paper 18697325 Paper 18694578 Paper 18656626 Paper 18608594 Paper 18565248 Paper 18518666 Paper 18512723 Paper 18511474 Paper 18413413 Paper 18383414 Paper 18372357 Paper 18301770 Paper 18299303 Paper 18260791 Paper 18257995 Paper 18250089 Paper 18236230 Paper 18182444 Paper 18165444 Paper 17921793 Paper 17875548 Paper 17766505 Paper 17720721 Paper 17666408 Paper 17665468 Paper 17664231 Paper 17650522

Abstract

This is a phase I-II trial of ingested interferon-alpha (IFN-a) in insulin dependent diabetes mellitus (IDDM), an autoimmune disease. It will study the effect of IFN-a on immune function and Beta cell function and destruction in IDDM. Subjects with newly diagnosed IDDM will be enrolled for a treatment period of up to 12 months. Establishment of clinical improvement or immunosuppression with ingested IFN-a may lead to a placebo-controlled phase II-III trial with persistent improvement in clinical disease as a primary outcome.

View original record on NIH RePORTER →